Edward Chuong is one of five researchers nationwide awarded funding to pursue ‘daring, paradigm-shifting research’ on cancer immunotherapy treatment

Edward Chuong, a University of Colorado Boulder assistant professor of molecular, cellular and developmental biology and a BioFrontiers Institute scientist, has been awarded $1.25 million by the New York City-based Cancer Research Institute (CRI) to pursue his cancer immunotherapy research.

Chuong was one of five researchers nationwide who received the unrestricted funding over a five-year period, which CRI said is designed to allow researchers to pursue high-risk, high-reward projects that could redefine cancer treatment. The organization called the researchers “scientific leaders poised to reshape cancer immunotherapy through daring, paradigm-shifting research.”

 

Edward Chuong, a CU Boulder assistant professor of molecular, cellular and developmental biology and a BioFrontiers Institute scientist, recently was awarded $1.25 million by the Cancer Research Institute to pursue cancer immunotherapy research. 

“These are people who are hitting their stride scientifically and career-wise, and this is where you really want to put some jet fuel in the tank as they are getting established,” said Dr. E. John Wherry, associate director of CRI’s Scientific Advisory Council.

Echoing Wherry’s sentiment, Dr. Alicia Zhou, CRI chief executive officer, added, “Each of these researchers brings fearless curiosity and a willingness to challenge assumptions – the very qualities that drive breakthroughs. They aren’t just advancing cancer science; they are reinventing it.”

Chuong said he was surprised and honored to receive CRI funding for his research.

“As someone from an evolutionary biology background, this award means my outsider ideas are being welcomed into the cancer research community. It’s a huge boost,” he said.

Chuong’s research focuses on the role that ancient viral fragments in human DNA, called transposons, play in regulating immune cell signaling.

“Our lab started out exploring the evolution of transposons—bits of DNA derived from genetic parasites—and discovered they may function as hidden switches in our immune system,” Chuong said. “With this support, we’ll investigate how cancer cells hijack these switches to escape detection, and use that knowledge to develop new markers and therapies that make immunotherapy work better for more patients. I’m grateful to the Cancer Research Institute for supporting this unconventional perspective and I’m incredibly excited to see where it leads.”

Each year, CRI awards funding for scientists to pursue their research through its grant-making program honoring its founding scientific and medical director, Lloyd J. Old. The organization said its Lloyd J. Old STAR program—Scientists TAking Risks—is designed to provide long-term funding to mid-career scientists, giving them the freedom and flexibility to pursue research “at the forefront of discovery and innovation in cancer immunotherapy.”

CRI said its awards are given out based upon its “exceptional track record of identifying and supporting people who have had a major impact in immunotherapy.” The organization said its grants are not tied to a specific research project but rather support outstanding researchers based upon the quality and promise of researchers’ overall work. 

Did you enjoy this article? Subscribe to our newsletter. Passionate about molecular, cellular and developmental biology? Show your support.